Transcend Therapeutics Acquisition, Valuation, Funding & Investors

AdvanCell is a Melbourne-based clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer. Its lead candidate, AdVance-32, uses lead-212 isotopes conjugated to actinium-225 chelators to deliver cytotoxic radiation to prostate, ovarian, and neuroendocrine tumors. Phase 1 trials at Peter MacCallum Cancer Centre demonstrate tumor uptake with minimal off-target effects. AdvanCell manufactures isotopes at its lead-212 generator facility in Belgium.

Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.

Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

Angiocrine Bioscience is a New York-based biotechnology firm advancing stem cell expansion technologies. Its endothelial cell platform mimics the vascular niche to amplify hematopoietic stem cells ex vivo without serum or cytokines. Applications span regenerative medicine, cell therapies for blood disorders, and tissue engineering in human and mouse models.

CHO Pharma Inc is a biopharmaceutical company mainly focused on the development and commercialization of innovative products based on the proprietary glycan engineering technologies. It offers antibodies, such as CHO-H01, CHO-H02, CHO-A04 for cancer; CHO-H03, an antibody for autoimmune disease; CHO-S05 dual-effect anti-flu drugs; and CHO-V06 glycan-based vaccines and drugs.

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

NGM Biopharmaceuticals is a South San Francisco-based biotech firm discovering protein therapeutics for type 2 diabetes, obesity, and liver diseases based on human genetics and clinical insights. The company targets the gastrointestinal tract to mimic gastric bypass effects and collaborates with Merck on clinical-stage candidates like NGM313 for NASH treatment. Founded in 2008, NGM Biopharmaceuticals advances multiple assets into human trials.

SK Chemicals Co Ltd is mainly engaged in manufacturing chemical products in Korea. The Green Chemicals of the company include Copolyester, 3D Printing Materials, Coating, and Adhesive Material, Engineering Plastic and BioMaterial among others. The company is also involved in Life science business which includes Prescription Medicines, Vaccines, and OTC Medicines.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.

PT Tempo Scan Pacific Tbk operates in the pharmaceutical business in Indonesia. It is engaged in the production of tablet/caplets, effervescent powders, liquid/syrup, cream and ointment, and capsule dosage forms, and markets body care products. It operates through the following segments: The Pharmaceuticals segment, the Consumer Products and Cosmetics segment, and the Distribution Services segment. The company caters to both Indonesian and international markets.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets . The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically the company generates revenue from Brazil, Colombia, Argentina, Rest of LATAM, Canada, and Other, with the majority revenue generated from the Brazil region.

Sonoma Biotherapeutics is a South San Francisco-headquartered biotech firm engineering regulatory T-cell therapies for autoimmune diseases like celiac and inflammatory bowel conditions. Its allogeneic platform uses CRISPR editing for antigen-specific Tregs, advancing candidates through preclinical stages with manufacturing in Emeryville facilities.